Eric Chang serves as Executive Director in the Gilead Sciences corporate development group, where he currently heads transactions for inflammatory and fibrotic diseases. Over the last several years, he has contributed to the significant expansion of Gilead’s pipeline through R&D partnership and acquisition projects. Prior to joining the corporate development group, Eric held roles in corporate strategy focused on solving enterprise-level challenges and in new product planning for liver disease. Beyond Gilead, Eric served as VP Corporate Development at Star Therapeutics, a private-stage biotech company focused on developing novel therapies for patients with rare diseases. Prior to joining the biopharma industry, Eric began his career in equity research covering the biotech and pharma sectors at Bank of America Merrill Lynch, Oppenheimer, and JMP Securities. He holds a BS in Biomedical Engineering from Columbia University and an MBA from the University of California, Berkeley.